Lifecore Biomedical to be Acquired by Webster Equity Partners
Lifecore Common Stockholders to Receive $6.28 per Share in Cash at Closing, Representing a 49.5% PremiumLifecore Series A Preferred Stockholders Will Receive Required "Conversion Amount" per Share in Cash at ClosingBoth Common Stockholders and Series A Preferred Stockholders Will Receive Contingent Value Rights (CVRs) for Up to $160 Million in Aggregate Cash Payments Contingent Upon Achieving Performance MilestonesStockholders May Receive Up to $9.67 per Common Equivalent in Combined Cash and CVR at Full Performance Milestone PaymentsTransaction Expected to Support Lifecore’s Growth Objectives CHASKA, Minn. and WALTHAM, Mass., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (
